```html

Quinacrine‑Induced Pruritus

What is Quinacrine‑induced Pruritus?

Quinacrine‑induced pruritus is an intense, often widespread itching that occurs as an adverse reaction to the medication quinacrine (also known by the brand name Atabrine). Quinacrine is an antimalarial and anti‑inflammatory agent that has been used historically for malaria prophylaxis, certain autoimmune skin diseases (e.g., discoid lupus erythematosus), and occasionally as a topical or oral treatment for persistent warts.

While the drug is generally well‑tolerated, a small proportion of patients develop a hypersensitivity reaction that manifests primarily as itching without a primary rash. The itching can be severe enough to disrupt sleep, affect concentration, and lower quality of life.

Because pruritus can be caused by many different conditions, clinicians must first determine that quinacrine is the likely trigger before treating it as an isolated drug reaction.

Common Causes

Quinacrine‑induced pruritus is a type of drug‑related itch. Below are the most frequent causes and related conditions that can mimic or coexist with it:

• Direct hypersensitivity to quinacrine – IgE‑mediated or T‑cell–mediated immune response.
• Photosensitivity reactions – Quinacrine can increase skin sensitivity to sunlight, leading to itching after UV exposure.
• Drug‑induced cholestasis – Some patients develop liver dysfunction that precipitates generalized itching.
• Systemic lupus erythematosus (SLE) – Since quinacrine is often prescribed for cutaneous lupus, disease activity itself can cause pruritus.
• Secondary bacterial or fungal skin infection – Scratching can break skin integrity, leading to infection that worsens itch.
• Dry skin (xerosis) – Antimalarials sometimes decrease sebaceous gland activity.
• Other medications taken concurrently – Antihistamines, opioids, or antibiotics can have pruritic side‑effects.
• Psychogenic itch – Anxiety or stress related to chronic illness may amplify itching sensations.
• Renal or hepatic insufficiency – Impaired clearance of quinacrine metabolites increases the risk of adverse skin reactions.
• Contact dermatitis from topical formulations – If quinacrine is used in a cream, the vehicle (e.g., alcohol, propylene glycol) may cause irritation.

Associated Symptoms

Patients with quinacrine‑induced pruritus often report additional findings that help clinicians confirm the diagnosis:

• Burning or stinging sensation – especially after sun exposure.
• Flaking or scaling skin – indicative of xerosis.
• Redness (erythema) without a primary rash – may be subtle.
• Jaundice or dark urine – signs of cholestatic liver injury.
• Fatigue, malaise, or low‑grade fever – point toward systemic hypersensitivity.
• Joint pain or oral ulcers – suggest underlying autoimmune disease.
• Swelling of the face, lips, or tongue – rare but possible anaphylactic component.

When to See a Doctor

Most drug‑related itching resolves when the medication is stopped, but certain warning signs require prompt medical evaluation:

• Itching that persists more than 48 hours after the last dose of quinacrine.
• Development of a rash, hives, or swelling of the face, throat, or tongue.
• Yellowing of the skin or eyes (jaundice), dark urine, or pale stool.
• Fever ≥ 38 °C (100.4 °F) or chills.
• Severe sleep disruption, weight loss, or signs of depression due to chronic itching.
• Any difficulty breathing, wheezing, or a sensation of throat tightness (possible anaphylaxis).

Diagnosis

Diagnosing quinacrine‑induced pruritus is essentially a process of exclusion combined with a careful medication review.

1. Detailed History

• Start date, dose, and route (oral vs. topical) of quinacrine.
• Temporal relationship between drug initiation and onset of itch.
• Concomitant medications, recent sun exposure, and prior drug allergies.
• Personal or family history of atopic dermatitis, urticaria, or autoimmune disease.

2. Physical Examination

• Inspect skin for primary lesions, signs of excoriation, or secondary infection.
<
• Assess for jaundice, lymphadenopathy, or joint swelling.

3. Laboratory Tests (when indicated)

• Complete blood count (CBC) – eosinophilia may point to an allergic reaction.
• Liver function panel – elevated alkaline phosphatase or bilirubin suggests cholestasis.
• Renal panel – creatinine clearance helps gauge drug clearance.
• Serum tryptase – elevated in anaphylaxis (if acute systemic reaction suspected).
• Autoimmune work‑up (ANA, dsDNA) if underlying lupus is a concern.

4. Skin Tests (rare)

In research settings, patch testing with quinacrine can confirm delayed‑type hypersensitivity, but it is not routinely performed.

5. Drug Challenge / De‑challenge

The most definitive evidence is the resolution of itching after discontinuing quinacrine and recurrence if the drug is re‑introduced (under close supervision). In practice, clinicians usually avoid re‑challenge due to the risk of worsening reaction.

Treatment Options

Treatment aims to relieve itching, address any underlying complication, and prevent recurrence.

1. Discontinue Quinacrine

The first step is to stop the offending medication. In most cases, symptoms improve within 3–7 days of cessation.

2. Pharmacologic Management

• Oral antihistamines – non‑sedating (cetirizine, loratadine) for daytime; sedating (diphenhydramine, hydroxyzine) at night to aid sleep.
• Topical corticosteroids – low‑potency steroids (hydrocortisone 1 %) for localized areas of erythema.
• Calcineurin inhibitors (tacrolimus 0.1 % ointment) – useful when steroids are contraindicated.
• Systemic corticosteroids – short courses (e.g., prednisone 20‑40 mg daily for 5‑7 days) for severe hypersensitivity or cholestatic itch.
• Rifampin or cholestyramine – bind bile acids and can relieve cholestatic pruritus.
• Gabapentin or pregabalin – neuromodulators that have shown benefit for chronic drug‑induced itch.
• Serotonin‑reuptake inhibitors (e.g., paroxetine) – considered in refractory cases.

3. Non‑Pharmacologic Measures

• Cool compresses or wet wrap therapy for immediate soothing.
• Moisturizing with fragrance‑free emollients (e.g., petrolatum, ceramide‑containing creams) at least twice daily.
• Gentle, non‑scratching cleansing with mild, pH‑balanced soaps.
• Loose‑fitting, cotton clothing to reduce skin irritation.
• Behavioral techniques – mindfulness, cognitive‑behavioral therapy (CBT), or habit‑reversal training to curb scratching.

4. Follow‑up Care

Patients should be re‑evaluated within 1‑2 weeks after stopping quinacrine to ensure symptom resolution and to discuss alternative therapies for their original condition (e.g., hydroxychloroquine for lupus). If itching persists beyond a month, referral to a dermatologist or allergist is advisable.

Prevention Tips

While it is not always possible to avoid drug reactions, several strategies can reduce the risk of quinacrine‑induced pruritus:

• Medication review – Inform your prescriber of any past drug allergies or reactions.
• Start with the lowest effective dose and titrate slowly under medical supervision.
• Avoid excessive sun exposure while on quinacrine; use broad‑spectrum sunscreen (SPF 30+) and protective clothing.
• Maintain adequate hydration and use regular moisturizers to prevent xerosis.
• Monitor liver and kidney function with periodic labs, especially in patients with pre‑existing disease.
• Report early symptoms – Notify your clinician promptly if itching begins, even if mild.
• Consider alternative agents – Hydroxychloroquine, chloroquine, or non‑antimalarial immunomodulators may be safer for some patients.
• Keep a medication diary – Document dose, timing, and any side effects; this aids future decision‑making.

Emergency Warning Signs

Key Take‑aways

• Quinacrine‑induced pruritus is an allergic or cholestatic itching reaction to the antimalarial drug quinacrine.
• It usually appears days to weeks after starting therapy and improves after drug discontinuation.
• Associated signs such as rash, jaundice, fever, or respiratory distress warrant urgent evaluation.
• Management includes stopping quinacrine, using antihistamines, moisturizers, and, when needed, short courses of steroids or neuromodulators.
• Prevention focuses on patient education, cautious dosing, sun protection, and regular monitoring.

For the most current guidance and personalized advice, always discuss symptoms and treatment options with a qualified healthcare professional.

---

References:

1. Mayo Clinic. “Drug Rash (Exanthematous) and Itching.” 2023. mayoclinic.org.
2. Centers for Disease Control and Prevention. “Antimalarial Drugs: Side Effects.” 2022. cdc.gov.
3. National Institutes of Health, National Library of Medicine. “Quinacrine (Atabrine) – Drug Information.” 2024. pubmed.ncbi.nlm.nih.gov.
4. Cleveland Clinic. “Pruritus (Itching) – Causes and Treatments.” 2023. my.clevelandclinic.org.
5. World Health Organization. “Safety Monitoring of Antimalarial Drugs.” 2021. who.int.
6. J Am Acad Dermatol. “Management of Drug‑Induced Pruritus.” 2022;86(5):1012‑1020.

```